Clinical Trials to Treat Childhood Astrocytoma
Entinostat in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment. Entinostat may block some of the enzymes needed for cell division and it may help to kill tumor cells.
Location: 21 locations
Selumetinib in Treating Young Patients with Recurrent or Refractory Low Grade Glioma
This phase I / II trial studies the side effects and the best dose of selumetinib and how well it works in treating or re-treating young patients with low grade glioma that has come back (recurrent) or does not respond to treatment (refractory). Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Location: 13 locations
Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
The purpose of this study is to investigate the activity of dabrafenib in combination with trametinib in children and adolescent patients with BRAF V600 mutation positive low grade glioma or relapsed or refractory high grade glioma.
Location: 7 locations
Fimepinostat in Treating Younger Patients with Relapsed or Refractory Solid Tumors, Central Nervous System Tumors, or Lymphoma
This phase I trial studies the side effects of fimepinostat in treating younger patients with solid tumors, central nervous system tumors, or lymphoma that has come back or does not respond to treatment. Fimepinostat may stop the growth of cancer or tumor cells by blocking some of the enzymes needed for cell growth.
Location: 5 locations
INFUSE Bone Graft in Treating Patients with Tibial Pseudarthrosis and Neurofibromatosis 1 Undergoing Surgery
This randomized phase II trial studies how well INFUSE bone graft works in treating patients with tibial pseudarthrosis and neurofibromatosis 1 undergoing surgery. INFUSE bone graft containing recombinant human bone morphogenetic protein-2 and absorbable collagen sponge may increase the rate of healing of the tibia bone.
Location: 11 locations
Adult Study: ABT-414 Alone or ABT-414 Plus Temozolomide vs. Lomustine or Temozolomide for Recurrent Glioblastoma Pediatric Study: Evaluation of ABT-414 in Children With High Grade Gliomas (INTELLANCE 2)
This study is to evaluate the efficacy and safety of ABT-414 alone or with temozolomide versus temozolomide or lomustine alone in participants with recurrent glioblastoma multiforme. The study includes a Pediatric sub-study to evaluate safety, tolerability and pharmacokinetics of ABT-414 in a pediatric population. Adult enrollment has been completed and the study is now only recruiting for pediatric participants.
Location: 4 locations
Trial of Afatinib in Pediatric Tumours
Open-label, dose escalation, monotherapy, basket trial with biomarker specific MTD expansion cohort / Phase II part. The trial will consist of 2 parts: 1. Dose finding part to determine the MTD 2. Biomarker specific MTD expansion cohort / Phase II part to assess clinical anti-tumour activity in included tumour types
Location: 3 locations
Recombinant Oncolytic Poliovirus PVS-RIPO in Treating Children with Recurrent Malignant Glioma
This phase Ib trial studies the side effects of recombinant oncolytic poliovirus PVS-RIPO in treating children with glioma that has come back after a period of improvement. Vaccines made from a gene-modified virus may help the body build an effective immune response to kill tumor cells and reduce tumor size.
Location: Duke University Medical Center, Durham, North Carolina
Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas
This phase II trial studies how well peginterferon alfa-2b works in treating younger patients with pilocytic astrocytomas or optic pathway gliomas that have come back or do not respond to treatment and are growing, spreading, or getting worse. Peginterferon alfa-2b may stop tumor growth by preventing cell division and formation of blood vessels in the tumor, and by activating the immune system to attack tumor cells.
Location: Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia